Thylakoid engineered M2 macrophage for sonodynamic effect promoted cell therapy of early atherosclerosis  

作　　者：Guanghao Wu Changwen Mu Qianru Zhao Yao Lei Ran Cheng Weidong Nie Jiamin Qu Yuping Dong Ruili Yang Haiyan Xie 

机构地区：[1]State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Chemical Biology Center,Peking University,Beijing 100191,China [2]School of Materials Science and Engineering,Beijing Institute of Technology,Beijing 100081,China [3]School of Life Science,Beijing Institute of Technology,Beijing 100081,China [4]School of Stomatology,Peking University,Beijing 100081,China

出　　处：《Nano Research》2024年第4期2919-2928,共10页纳米研究（英文版）

基　　金：supported by the National Science Fund for Distinguished Young Scholars(No.22025401);the National Natural Science Foundation of China(Nos.21874011,and 22104005);China Postdoctoral Science Foundation(Nos.2021TQ0037,and 2021M690405).

摘　　要：Atherosclerosis is the most common cause of cardiovascular diseases that contribute to the major morbidity worldwide,but still lacking of effective treatment strategy.Here,a hybrid cell is constructed for the sonodynamic effect promoted cell therapy of early atherosclerosis by fusing M2 macrophages with thylakoid(TK)membranes.After systemic administration,the obtained TK-M2 actively accumulates in the early atherosclerotic plaques,wherein M2 macrophages relieve the cholesterol accumulation and the inflammation in the foam cells.Meanwhile,the TK membranes decorated on the M2 macrophages exhibit both type I and type II sonodynamic effects under ultrasound(US)activation,inducing the direct apoptosis of foam cells.The cooperation of M2 and TK leads to significant outcome in eliminating atherosclerotic plaques without obvious side-effects,providing a new avenue for atherosclerosis treatment.

关 键 词：ATHEROSCLEROSIS THYLAKOID ULTRASOUND M2 macrophage 

分 类 号：R543.5[医药卫生—心血管疾病]